FDA Panel at ARDD2026: Matching Clinical Trials of Therapeutics & Regulatory Mandates

Value of the Information & Strength of the Argument

The value of this discussion lies in its direct, authoritative insights from FDA officials actively engaged in drug review and regulatory science. The arguments are well-structured, with officials outlining a stepwise approach from traditional disease-specific outcomes to broader aging indications. The panel effectively uses analogies (e.g., insulin’s early mortality trials, G-factor for cognition) to illustrate the potential evolution of the field. They also address practical challenges such as benefit-risk for decades-long treatments and the need for enriched trials. The reasoning is grounded in FDA regulatory frameworks (e.g., surrogate endpoints, accelerated approval) and emphasizes evidence-based decision-making. However, the discussion is largely expert opinion, lacking specific data or published evidence, but it provides a clear roadmap for sponsors. The panelists are consistent and complementary, strengthening the overall argumentation.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high given the panelists’ roles: Jeffrey Siegel heads the Office of Drug Evaluation Sciences, Steven Kozlowski is FDA Chief Scientist, Justin Penzenstadler is an associate director in the clinical review office responsible for aging indications, and Lowell Zeta is acting chief of staff. Their contributions are grounded in FDA policies and regulatory experience. Sources directly mentioned include the BEST glossary (a collaborative NIH-FDA biomarker glossary) and the intrinsic capacity concept, although no URLs were provided. The description lists the ARDD organization website and LinkedIn, which serve as primary references for the conference and organizers. The title perfectly matches the content: the panel focuses on aligning clinical trial endpoints with regulatory mandates, and the discussion stays on topic throughout. No significant discrepancies between title and content are noted.

The title accurately reflects the panel's focus on regulatory pathways for aging therapeutics, as the discussion centers on matching clinical trial designs with regulatory mandates.

9/10

High reliability due to direct input from FDA senior officials at a specialized conference, sharing regulatory perspectives and current policy considerations.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 01:30Introduction of panelists and their roles at FDA, emphasizing the agency's interest in longevity science.
• 05:30Jeffrey Siegel outlines two potential regulatory approaches for aging therapies: showing effects on multiple co-morbidities or defining a broad aging indication using intrinsic capacity.
• 09:30Justin Penzenstadler discusses the evolution of endpoints, drawing parallels to early insulin trials and the potential for comorbidity or mortality endpoints in enriched populations.
• 13:30Steven Kozlowski proposes the idea of a 'G-factor for aging' and emphasizes the need for shared pre-competitive endpoints and longitudinal data to build regulatory science.
• 17:30Lowell Zeta suggests that resolving whether aging is a disease is not necessary; instead, focusing on endpoint science and tool development is more productive.

• AgingPharma.org - ARDD Conference Website — Official website for the Aging Research and Drug Discovery (ARDD) meeting, providing conference information and updates.
• ARDD LinkedIn Page — LinkedIn page for ARDD, used to follow conference news and updates for future meetings.